1 – 10 of 139
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
2024) In The Lancet Haematology(
- Contribution to journal › Article
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
2024) In Haemophilia(
- Contribution to journal › Article
- 2023
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
(
- Contribution to journal › Article
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
-
Mark
Koagulationsfaktor XIII – inte bara ett kongenitalt blödningsproblem
(
- Contribution to journal › Scientific review